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Despite the astonishing progress in treating chronic hepatitis C virus (HCV) infection with 
direct-acting antiviral agents, liver fibrosis remains a major health concern in HCV infected 
patients, in particular due to the treatment cost and insufficient HCV screening in many 
countries. Only a fraction of patients with chronic HCV infection develop liver fibrosis. While 
there is evidence that host genetic factors are involved in the development of liver fibrosis, 
the common variants identified so far, in particular by genome-wide association studies, 
were found to have limited effects. Here, we conducted an exome association study in 
88 highly selected HCV-infected patients with and without fibrosis. A strategy focusing 
on TGF-β pathway genes revealed an enrichment in rare variants of the endoglin gene 
(ENG) in fibrosis patients. Replication studies in additional cohorts (617 patients) identified 
one specific ENG variant, Thr5Met, with an overall odds ratio for fibrosis development 
in carriers of 3.04 (1.39–6.69). Our results suggest that endoglin, a key player in TGF-β 
signaling, is involved in HCV-related liver fibrogenesis.
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INTRoDUCTIoN
End-stage chronic hepatitis C is the leading cause of liver 
transplantation in developed countries, despite the advent of 
potent antiviral drugs (Chhatwal et al., 2016). The pathogenesis of 
severe complications of chronic HCV infection remains unclear 
(Chhatwal et al., 2016). Most individuals with chronic HCV 
infection never develop cirrhosis, whereas others develop severe 
liver fibrosis in less than 20 years (Patin et al., 2012; Rueger et al., 
2015). Known common risk factors for liver fibrosis progression 
include several host characteristics (e.g., male sex, older age at 
infection, HIV/HBV co-infection, metabolic syndrome, alcohol 
consumption) and viral factors (e.g., genotype 3) (Rueger et al., 
2015). However, these factors explain only a small proportion 
of the inter-individual variability in liver fibrosis development 
(Patin et al., 2012), and there is evidence for the involvement of 
largely unidentified human genetic factors in fibrosis progression 
(Matsuura and Tanaka, 2018).
Several association studies have assessed the impact of 
common variants (polymorphisms) on liver fibrosis progression 
(Matsuura and Tanaka, 2018). In particular, two large genome-
wide association studies (GWAS) on liver fibrosis have been 
conducted in HCV-infected HIV-negative (i.e., mono-infected) 
patients. The first, in a Caucasian population, identified four 
susceptibility loci, three of which are related to genes involved 
in apoptosis (Patin et al., 2012). The second, conducted in 
Japan, detected variants within the HLA region (Urabe et al., 
2013). Finally, a GWAS in Caucasian patients with HCV/HIV 
co-infection detected another locus on chromosome 3p25 
(Ulveling et al., 2016). These common variants have limited 
effects and could not explain the considerable variability in 
liver fibrosis development. Lower-frequency variants with 
stronger individual effects, particularly in coding regions, may 
instead be involved, and this hypothesis can now be tested by 
whole-exome sequencing (WES).
Transforming growth factor-β (TGF-β) is a key regulator of 
fibrosis (Meng et al., 2016) and is strongly involved in chronic 
liver disease contributing to all stages of disease progression 
from initial liver injury to fibrosis, cirrhosis, and hepato-cellular 
carcinoma (Dooley and ten Dijke, 2012; Fabregat et al., 2016). 
High levels of TGF-β result in activation of hepatic stellate cells 
(HSC) to myofibroblasts and massive hepatocyte cell death, which 
contributes to the promotion of liver fibrosis and later cirrhosis 
(Tsuchida and Friedman, 2017; Bansal and Chamroonkul, 2019). 
TGF-β1 promotes fibrosis through the well described TGF-β1/
TGFBR1 canonical pathway (Fabregat et al., 2016; Meng et al., 
2016). TGF-β1 binds to TGF-β receptor 2 (TGFBR2) which 
recruits and activates TGFBR1 (also known as ALK5). Active 
TGFBR1 phosphorylates Smad2 and Smad3 which form a 
complex with Smad4. These heteromeric complexes translocate 
to the nucleus to stimulate transcription of profibrotic molecules. 
Inhibitory Smad7 is a negative regulator of Smad2 and Smad3. 
In the present work, we focused on the TGF-β pathway, and we 
report here the results of a case-control exome-based association 
study investigating the role of rare and low frequency variants 
in 707 genes connected to this pathway in a cohort of highly 
selected patients with chronic HCV infection.
MATERIALS AND METHoDS
Study Subjects
Patients of the discovery cohort were selected from the French 
cohort of a previous GWAS of liver fibrosis progression in 
HCV mono-infected patients (Patin et al., 2012) [the ANRS 
Genoscan Study Cohort described elsewhere (Patin et al., 
2012; Ulveling et al., 2016)]. We selected patients from Paris 
Hospitals (Cochin and La Pitié-Salpêtrière) with an extreme 
fibrosis phenotype determined by the examination of a liver 
biopsy specimen and the duration of HCV infection until liver 
biopsy. The severe fibrosis group included 48 patients (cases) 
who developed severe fibrosis (METAVIR score F3 or F4) in less 
than 30 years after the presumed date of HCV infection (mean 
duration = 18.8 y; SD = 6.8 y) without major comorbidities. 
The control group included 40 patients who did not develop 
fibrosis (METAVIR score F0 or F1) more than 20 years after the 
presumed date of HCV infection in the absence of treatment 
(mean = 30.3 y; SD = 7.8 y; Table 1).
Whole Exome Sequencing (WES) and 
Variant Detection
WES was performed on an Illumina HiSeq 2500 by Agilent 
SureSelect All Exons V4 + UTRs (71 Mb) Single-Sample Capture 
at the Genomics Core Facility of the Imagine Institute (Paris, 
France). We used the Genome Analysis Software Kit (DePristo 
et al., 2011) (GATK v3.3) best practice pipeline to analyze our 
WES data. Reads were aligned with the human reference genome 
(hg19) with the maximum exact matches algorithm in Burrows–
Wheeler Aligner (Li and Durbin, 2010). Local realignment 
around indels were performed with the GATK (McKenna 
et  al., 2010). PCR duplicates were removed with Picard tools 
(broadinstitute.github.io/picard/). The GATK base quality score 
recalibrator (BQSR) was applied to correct sequencing artifacts. 
Individual genomic variant call files (gVCF) were generated with 
GATK HaplotypeCaller, and joint genotyping was performed 
with GATK GenotypeGVCFs. The calling process targeted 
regions covered by the WES Agilent 71-Mb Kit, including 200 
bps flanking each region.
Variant Level Quality Control
We filtered out sample genotypes with a coverage < 8X, a 
genotype quality (GQ) < 20, or a ratio of reads for the less 
covered allele (reference or variant allele) over the total 
number of reads covering the position (minor read ratio, 
MRR) < 20%, using an in-house script (Belkadi et al., 2015). 
We filtered out variant sites (i) multi-allelic (> 2 alleles), (ii) 
with more than 5% of missing genotypes, and (iii) flagged as 
probable false-positive variant sites by GATK Variant Quality 
Score Recalibrator (VQSR). The VQSR model was trained 
and applied for single nucleotide variants (SNV) and indels 
following the GATK best practices. We seek to achieve 99 
and 95% sensitivities to the accessible sites in the truth set for 
SNVs and indels, respectively. A set of 439,790 high quality 
variants was retained for the analysis.
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Sample Level Quality Control
We required that each individual sample had a minimum 8X 
coverage for at least 80% of the targeted bases. We checked 
that reported sex was concordant with that inferred from 
sequence data. We further look at the distribution of the 
transition/transversion (Ti/Tv) ratio, the het/nonref-hom 
ratio, the indels/SNPs ratio, and the call rate for high quality 
variants in consensus coding regions. The median Ti/Tv ratio 
was 3.14, ranging from 3.07 to 3.24, as expected for coding 
regions. The median het/nonref-hom ratio was 1.59, ranging 
from 1.37 to 1.83, as expected for samples mainly from 
European origin (Wang et al., 2015). The median indel/SNP 
ratio was 0.017, ranging from 0.016 to 0.019 and consistent 
with the 1:43 ratio previously observed in coding regions 
(Ng et al., 2008). Finally, all the samples had a final call rate 
greater than 90% in coding regions and were kept for further 
analyses. Principal component analysis of our 88 samples with 
1,000 genomes samples using high quality variants with minor 
allele frequency in the cohort ≥ 0.02 (Belkadi et al., 2016) 
confirmed that most patients were of European origin except 
five patients. Four patients (two cases and two controls) were 
of North African origin, and one case was very likely of mixed 
European and Asian origin (Supplementary Figure 1). We 
decided to keep those five patients and to adjust all association 
analyses on the three first principal components.
Variant Selection
We focus our analyses on the most likely functionally relevant 
variants based on several variant annotations. Variant effects 
were predicted using snpEff v4.2 (Cingolani et al., 2012) and 
the Ensembl GRCh37.75 reference database. For variants that 
have different annotations due to multiple transcripts of the 
gene, the highest impact effect for each variant was taken. 
Additional annotations including variant frequencies in ExAC 
populations (Lek et al., 2016), the Combined Annotation 
Dependent Depletion (CADD) score (Kircher et al., 2014), and 
the gene specific Mutation Significance Cutoff (MSC) (Itan et 
al., 2016) were performed using variant tools (San Lucas et al., 
2012). Candidate coding variants (CCV) were finally defined as 
missense, splice acceptor, splice donor, stop gained, stop loss, 
start loss, initiator codon variant, exon loss, frameshift, and 
in-frame insertions/deletions with a CADD score greater than 
the MSC, and with an ExAC frequency in the European non-
Finnish population below 0.05.
TABLE 1 | Clinical and demographic characteristics of chronically HCV infected patients of the discovery cohort (N = 88), the French replication cohort (N = 161), and 
the Swiss replication cohort (N = 453).
Covariate Category Discovery cohort French replication cohort Swiss replication cohort
No 
fibrosis
Severe 
fibrosis
Total (%) No 
fibrosis
Severe 
fibrosis
Total (%) No 
fibrosis
Severe 
fibrosis
Total (%)
N = 40 N = 48 N = 88 N = 102 N = 59 N = 161 N = 148 N = 308 N = 456
Sex Female 22 25 47 (53.4%) 61 22 83 (51.5%) 74 90 164 (36%)
METAVIR score F0 13 – 13 (14.8%) 15 – 15 (9.3%) 39 – 39 (9%)
F1 27 – 27 (30.7%) 87 – 87 (54.0%) 106 – 106 (23%)
F3 – 32 32 (36.3%) – 30 30 (18.6%) – 128 128 (28%)
F4 – 16 16 (18.2%) – 29 29 (18.0%) – 180 180 (40%)
Alcohol 
consumption (a)
Low 40 42 82 (93.1%) 91 40 131 
(81.4%)
65 126 191 (42%)
High – 7 7 (7.9%) 11 19 30 (18.6%) 80 181 261 (58%)
HCV mode of 
acquisition
IDU 9 16 25 (28.4%) 39 21 60 (37.3%) 54 101 155 (34%)
Blood 
transfusion
22 23 45 (51.1%) 41 29 70 (43.4%) 35 60 95 (21%)
Other/NA 9 9 18 (20.5%) 22 9 31 (19.3%) 56 147 203 (45%)
HCV genotype 1 25 34 59 (67.0%) 77 39 116 
(72.0%)
90 142 232 (51%)
2 9 1 10 (11.4%) 6 2 8 (5.0%) 13 38 51 (11%)
3 1 8 9 (10.2%) 13 12 25 (15.5%) 24 91 115 (25%)
4 1 2 3 (3.4%) – – – 16 30 46 (10%)
Other/NA 4 3 7 (7.9%) 6 6 12 (7.5%) 2 7 9 (2%)
Age at infection 
(y) (b)
Median 
(Q1–Q3)
18 
(11.5–23)
29 (22–39) 21 (17–27) 36 (21–46) 15 
(8–18.5)
23 
(17–27.5)
Duration of 
infection (y) (c)
Median 
(Q1–Q3)
30 
(24–34.5)
18 (14–26) 24 (21–29) 16 (12–19) 32 (27–36) 25 (18–31)
(a)The threshold to define high alcohol consumption in the French cohorts and in the Swiss replication cohort were ≥30g/d and ≥40g/d, respectively. Alcohol 
consumption was missing in one patient with severe liver fibrosis in the Swiss replication cohort.
(b)Age at infection was missing in 77 patients with severe liver fibrosis in the Swiss replication cohort.
(c)Duration of infection was missing in 77 patients with severe liver fibrosis in the Swiss replication cohort.
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Gene Selection
In the present work, we focused on the TGF-β signaling 
pathway, the central driver of liver fibrosis (Meng et al., 2016). 
We selected the seven main core genes of this pathway: TGFB1, 
TGFBR1, TGFBR2, SMAD2, SMAD3, SMAD4, and SMAD7 and 
further increased the list of genes of interest to 707 autosomal 
genes directly connected to those 7 core genes according to the 
human gene connectome (Itan et al., 2013), i.e., we retained only 
the genes connected to at least one of the 7 main core genes at 
a degree of connectivity of 1 (Supplementary Table 1). Within 
those 707 genes of interest, we identified 1,243 high quality CCV 
as defined in the variant selection section.
Statistical Analysis
To test whether rare candidate coding variants contribute to 
fibrosis, we collapsed candidate coding variants into a single 
burden variable which takes the value 1 if the patient carries at 
least one CCV and 0 otherwise and we compared the aggregated 
carrier frequency of candidate coding variants between cases and 
controls by logistic regression, as implemented in the R software 
using the glm function. Since principal component analysis 
identified five patients of non-European origin (Supplementary 
Figure 1), the analyses were adjusted on the three first principal 
components. We overcame the problem of the small sample 
size by restricting our analysis to 116 genes for which candidate 
coding variants were carried by more than five individuals 
leading to a Bonferroni corrected threshold of p < 0.00043 to 
account for multiple testing.
Replication Studies
To replicate our results, we first performed targeted next-
generation sequencing focusing on the coding regions of 
the endoglin gene on the same Illumina HiSeq2500 using a 
customized SureSelect gene panel in 161 additional Caucasian 
HCV mono-infected patients from the ANRS Genoscan Study 
Cohort, including 59 who developed severe liver fibrosis 
(METAVIR F3–F4) after a mean duration of 16.5 years of 
infection (SD = 5.5 years), and 102 patients who were fibrosis-
free (METAVIR F0-F1) after a mean duration of infection of 25.9 
y (SD = 5.8 years; Table 1).
We further investigated the association of rs35400405 with 
fibrosis in HCV mono-infected patients, in an additional cohort 
of 456 patients (308 severe fibrosis patients with METAVIR 
F3–F4 and 148 fibrosis-free patients with METAVIR F0–F1) 
of Caucasian origin from Switzerland (the Swiss Hepatitis C 
Cohort Study) with chronic HCV mono-infection (Table 1). In 
this cohort, rs35400405 was genotyped using a fluorescent based 
competitive allele specific polymerase chain reaction (KASP, LGC 
Genomics, Hoddesdon, Herts, United Kingdom). All the methods 
used were performed in accordance with relevant guidelines 
and regulations.
RESULTS
Discovery Cohort
Results of the exome association study in the discovery cohort 
of 88 patients for the 116 genes of the TGF-β pathway with more 
than 5 CCV carriers are shown in Figure 1. The main signal 
observed was that for ENG, encoding endoglin, with a P-value of 
0.00037, which remained significant after Bonferroni correction 
(P-valuecorrected = 0.043). The P-value was an order of magnitude 
larger for the next most closely associated gene (Supplementary 
Table 2). For ENG, there were seven heterozygous carriers of 
at least one CCV in the severe fibrosis group and none in the 
control group. There were only three ENG candidate coding 
variants: Thr5Met found in four patients, Gly191Asp in two 
patients, and Pro131Leu in one patient (Supplementary Table 
3). Six of the seven carriers were of European origin, and one, 
carrying Gly191Asp, was of mixed ancestry, likely Eurasian 
(Supplementary Figure 1).
FIGURE 1 | Manhattan plot for the exome association analysis of 116 informative TGF-β pathway genes in the discovery cohort. The dotted red line represents the 
significance threshold after Bonferroni correction (p = 0.00043).
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Replication Studies
For replication of these results, we performed targeted next-
generation sequencing focusing on the coding regions of ENG 
in 161 additional Caucasian HCV mono-infected patients. No 
significant enrichment in ENG candidate coding variants was 
found in this replication cohort, mostly due to the presence of 
three novel rare candidate coding variants in the control group 
(Supplementary Table 3). However, the frequency of carriers 
of the most common CCV enriched in our discovery cohort, 
Thr5Met (c.14C > T), was higher among fibrosis patients (10.2%) 
than among controls (3.9%) in the replication cohort although 
not significant (P-value = 0.12).
We conducted a second replication study by genotyping 
Thr5Met (rs35400405) in a larger independent Swiss cohort of 
HCV mono-infected patients including 308 patients with liver 
fibrosis and 148 without fibrosis (Table 1). Thr5Met was found 
to be significantly more abundant (P-value = 0.032) in fibrosis 
patients (7.5%) than in controls (2.7%). Overall, when all cohorts 
were combined, the frequency of Thr5Met carriers was 8.0% in 
fibrosis patients and 2.8% in controls, resulting in an odds ratio 
of 3.04 (1.39–6.69; P-value = 0.0024; Table 2). The frequency of 
Thr5Met carriers in >50,000 Europeans in the gnomAD database 
(http://gnomad.broadinstitute.org/) was 4.1%, confirming an 
enrichment of this variant in fibrosis patients, and a depletion in 
those without fibrosis.
In Silico Analysis of Thr5Met Variant
The Thr5Met variant maps to exon 1 of ENG encoding the signal 
peptide (Figure 2A). Thr5Met was predicted to be benign by 
PolyPhen and tolerated by SIFT, but it is in very strong linkage 
disequilibrium with five SNPs (Figure 2B) one of which, 
rs45514697, is predicted to affect transcription factor binding 
(www.regulomedb.org). SNP rs45514697 is predicted to modify 
a regulatory motif for liver factor (LF)-A1 (also known as 
hepatocyte nuclear factor 4), which is involved in the expression 
of several liver-specific genes (Ramji et al., 1991), with a lower 
affinity for the rare allele (http://archive.broadinstitute.org/
mammals/haploreg/haploreg.php).
DISCUSSIoN
In the present study, we used a three-stage analysis to identify 
potential protein-coding variants that contribute to liver fibrosis 
development in HCV mono-infected individuals. In contrast 
to GWAS investigating common variants, we focused on more 
rare potentially damaging coding variants identified by WES 
in 707 candidate genes linked to the TGF- β signaling pathway. 
We identified one low frequency missense variant (Thr5Met) 
in ENG gene, encoding endoglin, associated with liver fibrosis 
development. Very interestingly, this variant is also in perfect 
linkage disequilibrium with rs45514697, an upstream ENG variant 
located in a regulatory region. The rare allele of rs45514697 which 
is at risk for liver fibrosis is predicted to strongly decrease the 
DNA-binding affinity for LF-A1, a transcription factor involved in 
the expression of several liver specific genes (Ramji et al., 1991).
Endoglin, also known as cluster of differentiation CD105, 
is a TGF-β co-receptor. Heterozygous LOF mutations of ENG 
cause hereditary hemorrhagic telangiectasia type 1 (HHT1), 
also known as Osler–Weber–Rendu disease, a rare autosomal 
dominant condition characterized by telangiectasias and 
arteriovenous malformations (Meurer et al., 2014). Interestingly, 
the three variants identified in the discovery cohort, Thr5Met, 
Pro131Leu, and Gly191Asp, were previously observed in HHT1 
patients (Cymerman et al., 2003; Abdalla et al., 2005; Fernandez 
et al., 2006; Olivieri et al., 2007; Fontalba et al., 2008). Variants 
Thr5Met and Gly191Asp are presently considered as non-
pathogenic polymorphisms (Abdalla and Letarte, 2006; Olivieri 
et al., 2007), consistently with their frequency in public databases 
(MAF > 1% in gnomAD European population). The pathogenic 
role of Pro131Leu in HHT is more debated as the variant is more 
rare (MAF = 0.001 in the gnomAD European population), was 
associated with reduced levels of endoglin (Cymerman et al., 2003; 
Fernandez et al., 2006), but was also found in healthy individuals 
(Abdalla and Letarte, 2006; Olivieri et al., 2007). We did not have 
direct information about HHT symptoms (such as epistaxis or 
telangiectasia) for the patients carrying ENG variants in our 
cohort. However, they had no contraindication to liver biopsy, and 
no signs of arterio-venous malformations were reported in the 
biopsy. Of note, 41–74% of HHT patients present liver involvement 
with hepatic vascular malformations (Buscarini et al., 2018). Livers 
with HHT can show nodular hyperplasia and fibrosis around the 
abnormal vessels which, associated with portal hypertension, may 
lead to a misdiagnosis of cirrhosis (Buscarini et al., 2018).
In addition to its well-established role in angiogenesis, there is 
evidence to suggest that endoglin is involved in fibrogenesis (Meurer 
et al., 2014). Endoglin is strongly expressed in profibrogenic cell 
types such as mesangial cells, cardiac fibroblasts, scleroderma 
fibroblasts, and HSCs which are the most fibrogenic cells of the 
liver. Indeed, endoglin plays a crucial role in TGF-β signaling and 
is thought to modulate the balance between the main profibrotic 
TGF-β1/TFBR1 signaling pathway and the TGF-β1/ACVRL1 
TABLE 2 | Distribution and overall effect of ENG Thr5Met on liver fibrosis progression in the discovery cohort and the French and Swiss replication cohorts.
Discovery French replication Swiss replication All Cohorts oR [95%CI] (a) P-value(a)
No 
fibrosis
Severe 
fibrosis
No 
fibrosis
Severe 
fibrosis
No 
fibrosis
Severe 
fibrosis
No 
fibrosis
Severe 
fibrosis
N = 40 N = 48 N = 102 N = 59 N = 148 N = 308 N = 290 N = 415
N carriers(b) (%) 0 (0) 4 (8.3%) 4 (3.9%) 6 (10.2%) 4 (2.7%) 23 (7.5%) 8 (2.8%) 33 (8.0%) 3.04 (1.39–6.69) 0.0024
(a)Computed by means of the likelihood ratio test in the logistic regression framework.
(b)All carriers were heterozygous for Thr5Met.
Frontiers in Genetics | www.frontiersin.org November 2019 | Volume 10 | Article 1024
Endoglin and HCV-Related Liver FibrosisAbout et al.
6
FIGURE 2 | ENG variant Thr5Met (rs35400405) is in a regulatory region and in strong linkage disequilibrium with a potential regulatory SNP, rs45514697. The X 
axis for chromosome 9 positions is presented in the same direction as the transcription of ENG. (A) Eng Variant Thr5met (Rs35400405) Is in a Regulatory Region. 
Figure is modified from UCSC Genome Browser on Human hg19/GRCh37 Assembly (http://genome.cse.ucsc.edu). The H3K27Ac histone mark is the acetylation 
of lysine 27 of the H3 histone protein. It is reported as an important enhancer mark that can distinguish between active and poised enhancer elements (Creyghton 
et al., 2010). Schema for layered H3K27Ac shows that ENG variant Thr5Met is in an active regulatory region. Schema of DNaseI hypersensitivity clusters confirms 
that ENG variant Thr5Met is in a region with high transcriptional activity. Moreover, several transcription factors are found to bind to this same region. (B) Linkage 
Disequilibrium (Ld) Patterns of Snps Located in the Vicinity of Thr5met (Rs35400405). The Y axis shows the LD as measured by R². SNPs are indicated by circles 
and numbers within circles indicate the potential regulatory function of the SNP as predicted by RegulomeDB score (http://www.regulomedb.org/). ENG variant 
Thr5Met (rs35400405) is in almost perfect linkage disequilibrium with five non-coding SNPs (R² from 0.95 to 1). One of them, rs45514697 (R² = 0.95), is likely to 
affect binding (RegulomeDB score = 2b).
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signaling pathway (Velasco et al., 2008), which has a less studied 
and more controversial role in fibrosis (Munoz-Felix et al., 2013). 
There are two isoforms of endoglin resulting from alternative 
splicing, the long (L-Eng) and the short (S-Eng) endoglin (Gougos 
and Letarte, 1990; Bellon et al., 1993). It was previously found that 
L-Eng, the predominant form, enhances ACVRL1 (also known 
as ALK1) (Velasco et  al., 2008) while S-Eng promotes TGFBR1 
(Blanco et al., 2008; Velasco et al., 2008) signaling pathways. It was 
also shown that endoglin mediates the crosstalk between the TGF-β 
and the fibronectin/integrin signaling pathways in endothelial cells 
(Tian et al., 2012). Interestingly, HCV core protein was recently 
reported to modulate endoglin signaling in liver pathogenesis by 
upregulating endoglin expression on cell surface and activating its 
downstream ACVRL1 signaling pathway (Kwon et al., 2017). In 
addition, patients with chronic HCV infection and liver cirrhosis 
were found to have high intrahepatic and circulating endoglin 
levels (Clemente et al., 2006).
Whether endoglin stimulates or inhibits fibrosis is still debated. 
Several in vitro studies have been conducted that support either 
hypothesis. In numerous cells types, such as mesangial cells, 
myoblasts, fibroblasts, or chondrocytes, endoglin regulates 
negatively TGF-β-induced extracellular matrix (ECM) protein 
expression (Diez-Marques et al., 2002; Guo et al., 2004; Obreo 
et al., 2004; Rodriguez-Barbero et al., 2006; Finnson and Philip, 
2012). Other experiments outlined a profibrogenic role of endoglin 
in HSC cell lines (Meurer et al., 2011; Meurer et al., 2013) or in 
scleroderma patient fibroblasts (Morris et al., 2011). In an in vivo 
mouse model of kidney fibrosis following ureteral obstruction, 
L-Eng overexpression was associated with higher amounts of 
type I collagen and fibronectin (Oujo et al., 2014). More recently, 
endoglin haploinsufficiency in mice was shown to differentially 
regulate ECM production in skin and cartilage (Alzahrani et al., 
2018). The conflicting results observed on the role of endoglin 
in fibrosis may lie in the respective contribution of the two splice 
variants L- and S-endoglin which differ in their cytoplasmic 
domain and could have antagonizing effects (Velasco et al., 2008; 
Munoz-Felix et al., 2016), and/or in differential effects according to 
tissues (Alzahrani et al., 2018) or experimental conditions.
In a more relevant murine model of liver fibrosis, endoglin 
deficiency in HSC was recently shown to significantly aggravate 
liver fibrosis in response to injury suggesting a protective role 
of endoglin against liver fibrosis (Alsamman et al., 2018). This 
is consistent with a putative hypomorphic role of the rare allele 
of rs45514697 in liver fibrosis risk, with a predicted decrease in 
affinity at the corresponding LF-A1 motif. Further functional 
studies of Thr5Met and rs45514697, in particular, are required 
in HSCs, to determine their role in endoglin expression and/or 
function and provide insight into the potential antifibrogenic 
role of endoglin in the liver. These results may open the way for 
new treatments aimed at targeting specific signaling pathways 
involved in liver fibrogenesis (Bansal and Chamroonkul, 2019).
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